DE602006010508D1 - Substituierte triazolderivate als oxytocinantagonisten - Google Patents

Substituierte triazolderivate als oxytocinantagonisten

Info

Publication number
DE602006010508D1
DE602006010508D1 DE602006010508T DE602006010508T DE602006010508D1 DE 602006010508 D1 DE602006010508 D1 DE 602006010508D1 DE 602006010508 T DE602006010508 T DE 602006010508T DE 602006010508 T DE602006010508 T DE 602006010508T DE 602006010508 D1 DE602006010508 D1 DE 602006010508D1
Authority
DE
Germany
Prior art keywords
oxytocinantagonists
triazone derivatives
substituted triazone
substituted
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006010508T
Other languages
English (en)
Inventor
Alan Daniel Brown
Andrew A Calabrese
David Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of DE602006010508D1 publication Critical patent/DE602006010508D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602006010508T 2005-01-20 2006-01-11 Substituierte triazolderivate als oxytocinantagonisten Active DE602006010508D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals
PCT/IB2006/000118 WO2006077496A1 (en) 2005-01-20 2006-01-11 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
DE602006010508D1 true DE602006010508D1 (de) 2009-12-31

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006010508T Active DE602006010508D1 (de) 2005-01-20 2006-01-11 Substituierte triazolderivate als oxytocinantagonisten

Country Status (32)

Country Link
US (5) US7557131B2 (de)
EP (1) EP1841758B1 (de)
JP (1) JP4124805B1 (de)
KR (1) KR100936854B1 (de)
CN (1) CN101107243B (de)
AP (1) AP2007004047A0 (de)
AR (1) AR055303A1 (de)
AT (1) ATE449091T1 (de)
AU (1) AU2006207300B2 (de)
BR (1) BRPI0606463A2 (de)
CA (1) CA2595569C (de)
CR (1) CR9219A (de)
DE (1) DE602006010508D1 (de)
DK (1) DK1841758T3 (de)
DO (1) DOP2006000014A (de)
EA (1) EA200701328A1 (de)
ES (1) ES2334517T3 (de)
GB (1) GB0501190D0 (de)
GT (1) GT200600024A (de)
HK (1) HK1113927A1 (de)
IL (1) IL184148A (de)
MA (1) MA29160B1 (de)
MX (1) MX2007008757A (de)
NL (1) NL1030961C2 (de)
NO (1) NO338420B1 (de)
PA (1) PA8660401A1 (de)
PE (1) PE20060875A1 (de)
TN (1) TNSN07275A1 (de)
TW (1) TW200637847A (de)
UY (1) UY29339A1 (de)
WO (1) WO2006077496A1 (de)
ZA (1) ZA200705718B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
EP1902051A1 (de) * 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Azacyclohexanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
CA2654792A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2009539885A (ja) * 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
EP2141994A4 (de) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals Mehrringverbindungen und ihre verwendungen
BRPI0906433A2 (pt) * 2008-01-31 2019-09-24 Sanofi Aventis indole-3-carboxamidas cíclicas, sua preparação e seu uso como farmacêutico
MX2010007661A (es) 2008-01-31 2010-08-03 Sanofi Aventis Azaindol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos.
EP2872487B1 (de) * 2012-07-16 2017-04-26 Fibrogen, Inc. Verfahren zur herstellung von isochinolinverbindungen
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
WO2018091687A1 (en) 2016-11-18 2018-05-24 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CA3047643A1 (en) 2016-12-21 2018-06-28 Jiangsu Hengrui Medicine Co., Ltd. Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
MX2019007360A (es) * 2016-12-28 2019-08-16 Jiangsu Hengrui Medicine Co Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
TW202016091A (zh) * 2018-06-20 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｏｔｒ抑制劑的可藥用鹽、晶型及製備方法
WO2019242646A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 催产素受体抑制剂的晶型及其制备方法
TWI711612B (zh) * 2018-06-27 2020-12-01 大陸商江蘇恒瑞醫藥股份有限公司 氮雜雙環基取代的***類衍生物的可藥用鹽、晶型及製備方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的***衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891339A1 (de) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitoren der farnesyl-protein transferase
CA2250204A1 (en) 1996-04-03 1997-10-09 Neville J. Anthony Inhibitors of farnesyl-protein transferase
EP0891356A1 (de) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitoren von farnesylprotein-transferase
EP1003374A4 (de) 1996-12-30 2000-05-31 Merck & Co Inc Inhibitoren von farnesyl-protein-transferase
ATE318602T1 (de) 1997-12-16 2006-03-15 Pfizer Prod Inc Kombination aus einem alpha-1-adrenorezeptor antagonisten und einem cgm pdev hemmer zur behandlung von impotenz
WO2001007032A1 (fr) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Inhibiteurs de differenciation th2
ATE250039T1 (de) 1999-10-15 2003-10-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
CA2389280C (en) 1999-11-15 2009-01-27 Janssen Pharmaceutica N.V. Triazoles as farnesyl transferase inhibitors
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
CZ20023763A3 (cs) * 2000-05-19 2003-03-12 Merck Patent Gmbh Derivát triazolu
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
EP1432687A2 (de) 2001-10-03 2004-06-30 Pharmacia Corporation Substitutierte fünfgliedrige polyzyclischen vebindungen für die selektive hemmung der koagulationskaskade
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
BRPI0414663A (pt) * 2003-09-22 2006-11-21 Pfizer derivados triazol substituìdos como antagonistas de oxitocina
CA2551038C (en) 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
EP1742932A1 (de) 2004-04-28 2007-01-17 Pfizer Limited 3-heterocyclyl-4-phenyl-triazolderivate als inhibitoren des vasopressin-v1a-rezeptors
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
KR20070091023A (ko) 2007-09-06
JP2008528476A (ja) 2008-07-31
AU2006207300B2 (en) 2011-03-03
US8207198B2 (en) 2012-06-26
GT200600024A (es) 2006-08-23
EP1841758B1 (de) 2009-11-18
US20150322042A1 (en) 2015-11-12
CR9219A (es) 2007-07-24
ATE449091T1 (de) 2009-12-15
MX2007008757A (es) 2008-03-10
DOP2006000014A (es) 2006-07-31
NL1030961A1 (nl) 2006-07-21
US20130137671A1 (en) 2013-05-30
US9023872B2 (en) 2015-05-05
NL1030961C2 (nl) 2007-01-12
US7557131B2 (en) 2009-07-07
NO20074177L (no) 2007-10-16
DK1841758T3 (da) 2010-01-18
US9394278B2 (en) 2016-07-19
CN101107243B (zh) 2010-11-24
WO2006077496A1 (en) 2006-07-27
IL184148A (en) 2013-06-27
AU2006207300A1 (en) 2006-07-27
US20090253674A1 (en) 2009-10-08
KR100936854B1 (ko) 2010-01-14
AP2007004047A0 (en) 2007-06-30
PA8660401A1 (es) 2006-09-08
NO338420B1 (no) 2016-08-15
UY29339A1 (es) 2006-08-31
CA2595569A1 (en) 2006-07-27
PE20060875A1 (es) 2006-09-04
GB0501190D0 (en) 2005-03-02
HK1113927A1 (en) 2008-10-17
TW200637847A (en) 2006-11-01
CA2595569C (en) 2010-07-20
US20170114040A1 (en) 2017-04-27
IL184148A0 (en) 2007-10-31
ZA200705718B (en) 2008-08-27
US10150752B2 (en) 2018-12-11
MA29160B1 (fr) 2008-01-02
BRPI0606463A2 (pt) 2009-06-30
EA200701328A1 (ru) 2007-12-28
JP4124805B1 (ja) 2008-07-23
ES2334517T3 (es) 2010-03-11
CN101107243A (zh) 2008-01-16
EP1841758A1 (de) 2007-10-10
AR055303A1 (es) 2007-08-15
US20060160786A1 (en) 2006-07-20
TNSN07275A1 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
ATE479676T1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
FR20C1027I2 (fr) Derives de tiglien-3-one
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
DK1919907T5 (da) Heterocyklisk forbindelse
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DK1937650T3 (da) Heterocykliske forbindelser
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
DE502006001027D1 (de) Cyanuraten
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
CR10039A (es) Derivados espirocíclicos
DOP2006000261A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
DE602006014973D1 (de) Neuartige cercosporamidderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition